ArticleEuropean journal of nuclear medicine and molecular imaging2016
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Mechanical dyssynchrony and diastolic dysfunction are common in LVH: a pilot correlation study using Doppler echocardiography and CZT gated-SPECT MPI.Scientific reports · 2018Trial
- Vascular changes in hypertrophic cardiomyopathy.Cardiovascular research · 2026Review
- Myocardial Perfusion Imaging with Cardiovascular Magnetic Resonance in Nonischemic Cardiomyopathies: An In-Depth Review of Techniques and Clinical Applications.Medicina (Kaunas, Lithuania) · 2025Review
- The Utility of Nuclear Imaging in Hypertrophic Cardiomyopathy: A Narrative Review.Journal of clinical medicine · 2025Review
- PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis.Diagnostics (Basel, Switzerland) · 2025Review
- Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy.The international journal of cardiovascular imaging · 2023Review
- Role of nuclear cardiology in diagnosis and risk stratification of coronary microvascular disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- Microvascular Dysfunction in Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2022Review
- EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging.European journal of nuclear medicine and molecular imaging · 2021Article
- Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.Heart (British Cardiac Society) · 2020Article
- Positron emission tomography (International journal of cardiology. Heart & vasculature · 2020Article
- Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Review
- Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.The American journal of cardiology · 2018Article
- Topics of nuclear medicine research in Europe.Annals of nuclear medicine · 2017Review
- Linking myofilaments to sudden cardiac death: recent advances.The Journal of physiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMyocardial blood flow <1.1 mL/min/g following dipyridamole (Dip-MBF) assessed by positron emission tomography (PET) was identified in 2003 as an important outcome predictor in hypertrophic cardiomyopathy (HCM), based on scans performed in the 90s. However, such extreme Dip-MBF impairment is rarely observed in contemporary cohorts. We, therefore, reassessed the Dip-MBF threshold defining high-risk HCM patients.
methodsDip-MBF was measured using
resultsGlobal Dip-MBF was 1.95 ± 0.85, ranging from 0.7 to 5.9 mL/min/g. Dip-MBF tertile cut-off values were: 0.73 to 1.53 mL/min/g (lowest), 1.54 to 2.13 mL/min/g (middle), and 2.14 to 5.89 mL/min/g (highest). During follow-up, lowest tertile Dip-MBF was associated with sevenfold independent risk of unfavorable outcome compared to the other two tertiles. Dip-MBF 1.35 mL/min/g was identified as the best threshold for outcome prediction. Regional perfusion analysis showed that all cardiac deaths (n = 4) occurred in patients in the lowest tertile of lateral wall Dip-MBF (≤1.72 mL/min/g); septal Dip-MBF was not predictive.
conclusionsDip-MBF confirms its role as potent predictor of outcome in HCM. However, the threshold for prediction in a contemporary cohort is higher than that reported in earlier studies. Dip-MBF impairment in the lateral wall, possibly reflecting diffuse disease extending to non-hypertrophic regions, is a sensitive predictor of mortality in HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.